Citius Oncology, Inc. CTOR
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 54 cents this year.
The 4-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | ◌ | ◌ | ◌ | ◌ |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | ◌ | ◌ | ◌ | ◌ |
| Income tax $B | 0.0 | 0.0 | 0.0 | ◌ |
| Net income $B | −0.0 | −0.0 | −0.0 | 0.0 |
| EPS, diluted $ | −0.34 | −0.31 | −0.19 | 0.12 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — |
| ROE % | −54.4 | −59.0 | −98.1 | 110.2 |
| Shares out B | 0.08 | 0.07 | 0.00 | 0.00 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 3 of the 4 fiscal years we could check. 30 checks were skipped: the balance sheet is not tagged before 2022. 14 checks were skipped: EPS is not tagged before 2021.